Cargando…

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir

The long-acting parenteral formulation of the HIV integrase inhibitor cabotegravir (GSK744) is currently being developed to prevent HIV infections, benefiting from infrequent dosing and high efficacy. The crystal structure can affect the bioavailability and efficacy of cabotegravir. However, the sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yanqiang, Luo, Hongyuan, Lu, Qianqian, Liu, Zeying, Liu, Jinyun, Zhang, Jiarui, Wei, Zhiyun, Li, Jinjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659202/ https://www.ncbi.nlm.nih.gov/pubmed/34885762 http://dx.doi.org/10.3390/molecules26237178

Ejemplares similares

Ab initio determination of crystal stability of di-p-tolyl disulfide
por: Hao, Xuan, et al.
Publicado: (2021)

Cabotegravir
Publicado: (2022)

Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors
por: Ye, Simin, et al.
Publicado: (2023)

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
por: Smith, Steven J., et al.
Publicado: (2018)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Binding affinity and mechanisms of SARS-CoV-2 variants
por: Han, Yanqiang, et al.
Publicado: (2021)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Ab Initio Prediction of the Phase Transition for Solid Ammonia at High Pressures
por: Huang, Lei, et al.
Publicado: (2020)

Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir
por: Patel, Parul, et al.
Publicado: (2018)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
por: Lou, Yu, et al.
Publicado: (2016)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
por: Whitfield, Thomas, et al.
Publicado: (2016)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
por: Smith, Jennifer A, et al.
Publicado: (2020)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Phase Transitions and Stabilities among Three Phases of Di-p-tolyl Disulfides
por: Ali, Imran, et al.
Publicado: (2022)

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
por: Zhou, Tian, et al.
Publicado: (2017)

A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug
por: Kulkarni, Tanmay A., et al.
Publicado: (2020)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
por: Wu, Yuan-ni, et al.
Publicado: (2022)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Cabotegravir Exposure of Zebrafish (Danio rerio) Embryos Impacts on Neurodevelopment and Behavior
por: Zizioli, Daniela, et al.
Publicado: (2023)

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
por: Letendre, Scott L, et al.
Publicado: (2020)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
por: Delany-Moretlwe, Sinead, et al.
Publicado: (2022)

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials
por: Patel, Parul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ljqao1t8k4h8t4o3evbd28tkp9